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Summary In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31
chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel
tubulin-binding agent. The drug was given as an i.v. bolus injection at 2 mg m 2 once every 3 weeks in an
outpatient setting. Prophylactic antiemetics were not routinely given. Of the 29 eligible patients, nine had been
treated surgically and three had received radiotherapy. The main toxic effects observed were stomatitis (34% of
cycles) and neutropenia (41% ofcycles). Neutropenic fever was rare (3% ofcycles). Twenty-seven patients were
evaluable for response. There were four partial responses (15%), while 13 patients (48%) showed stabilisation
of their disease. The median duration of response was 7 months (range 6.0-10.7 months) and median survival
from the start of rhizoxin treatment was 6 months (range 2-14.7 months). Rhizoxin as single agent shows
activity in patients with advanced NSCLC.
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Despite major efforts made over many years to improve the
diagnosis, prevention and treatment of lung cancer, it
remains the leading cause of cancer-related deaths in both
men and women in many countries. Surgery offers the best
chance of curing early non-small-cell lung cancer (NSCLC)
(Thomas and Rubinstein, 1990). Unfortunately, only a small
minority (15-25%) of patients with NSCLC (squamous cell
carcinoma, adenocarcinoma and large-cell anaplastic carci-
noma), are diagnosed with locally amenable disease and, even
for these, about 50% of patients ultimately die from their
disease, despite potentially curative interventions. The out-
come of chemotherapy for disseminated NSCLC is dis-
appointing. The activity of single agents has been extensively
tested in NSCLC with response rates ranging from 5-23%
(Bakowski and Crouch, 1983; Cohen and Perevodchikova,
1979; Joss et al., 1984; Cerny et al., 1994).
The role ofcombination chemotherapy in NSCLC is still a
matter of debate, because despite increased response rates
and possible symptom relief, the median survival time is still
poor (Rapp et al., 1988; Bonomi et al., 1989). Therefore the
further development of new active agents for NSCLC is of
great importance.
Rhizoxin is a novel compound isolated in Japan in the
early 1980s from the plant pathogenic fungus Rhizopus
chinesis (Hendriks et al., 1992), which causes rice seedling
blight. Rhizoxin is a 16-membered macrolide compound with
antifungal and antineoplastic activity. Rhizoxin has been
selected for study in clinical trials because of its broad-
spectrum activity in preclinical studies against murine
tumours and human tumour xenografts, its unique interac-
tion with tubulin, which prevents microtubule formation and
inhibits mitosis, and its clear anti-tumour activity in the
vincristine-resistant P-glycoprotein-expressing tumour cell
line (Tsuruo et al., 1986).
In phase I studies, rhizoxin was administered as an i.v.
bolus injection every 3 weeks, and the dose was increased
from 0.8 mg m-2 up to 2.6 mg m-2. Neutropenia, mucositis
and diarrhoea appeared dose related and dose limiting. The
maximum tolerated dose was 2.6 mg m-2 and a dose of
2.0 mg m-2 was recommended for phase II studies (Bissett et
al., 1992).
The EORTC-ECTG has conducted a multicentre prospec-
tive phase II trial aiming to assess response to therapy,
response duration and toxicity of rhizoxin in patients with
advanced NSCLC.
Patients and methods
The study was conducted in accordance with the declaration
of Helsinki. The study was approved by the local ethics
committee for each centre. Patients gave written informed
consent to take part in this study.
To be eligible for the trial patients were required to be
>s 18 years of age, have histologically or cytologically
confirmed progressive, locally advanced, unresectable or
metastatic NSCLC (squamous, large-cell undifferentiated or
adenocarcinoma). In order to be entered into the study
patients had to have uni- or bidimensionally measurable
lesions, World Health Organization (WHO) performance
status <2, life expectancy > 12 weeks, leucocyte count
>4 x 109 1-', platelets, > 100 x 109 1-', adequate renal and
hepatic function (serum creatinine level < 140 pmol 1` or
creatinine clearance >60 ml min-' and serum bilirubin
<26 jumol I1, GOT and GPT not greater than three times
the normal respectively). Exclusion criteria were: previous or
concurrent chemotherapy; previous radiotherapy to the site
of the index lesion used to assess response; active infection;
symptomatic leptomeningeal or brain metastasis; second
malignancy and concurrent treatment with other investiga-
tional drugs. Pretreatment investigation included documenta-
tion of the patients' medical history, a physical examination
and the WHO performance score. A full blood count,
biochemistry profile, renal and hepatic function tests, chest
radiography and/or thoracic CT, an abdominal CT scan or
echography were also routinely performed.
These same parameters were repeated for follow-up
purposes every 3 weeks before each treatment course.
Radiological and ultrasound investigation of all measurable
lesions for response assessment as well as thoracic CT (when
the sole means of evaluation) were performed every two
cycles. The NCI common toxicity criteria (CTC) was used for
toxicity grading.
Correspondence: S. Kaplan, Abteilung fur Onkologie, Kantonsspital
Basel, 4031 Basel, Switzerland
Received 1 June 1995; revised 15 August 1995; accepted 23 August
1995Rhizoxin in non-small-cell lung cancer
S Kaplan et al
The response to therapy was assessed according to the
standard WHO criteria. The first response evaluation was
performed 6 weeks after entry into the study. Progression
could not be defined before 3 weeks (one full cycle). A
progression observed between 3 and 6 weeks after study entry
was defined as 'early progression'.
Treatment
Each vial containing 5 mg of rhizoxin was reconstituted in
2.5 ml of special diluent composed of 80% propylene glycol
and 20% ethanol. After complete dissolution had been
obtained, 2.5 ml of sterile water for injection was added to
produce a solution containing 1 mg ml-'. Further dilution
was not permitted as the drug precipitates in saline and
dextrose solutions. Rhizoxin was administered at a dose of
2 mg m-2, as a bolus, by direct i.v. injection, once every 3
weeks in an outpatient setting.
Dose modification
Dose reduction was based upon haematological toxicity. A
treatment delay of 1 week was required if on day 22 the
leucocyte count was < 3 x 109 I` or the platelets count was
< 100 x 109 1-'.
When such a delay occurred the dose was reduced by 25%
of the previous dose. Dose reduction was mandatory under
these circumstances. The dose was reduced in the same way
in the case of documented episodes of either bleeding with
thrombocytopenia or febrile neutropenia requiring hospitali-
sation. For all other grade 2 non-haematological toxicity,
such as skin reaction, stomatitis, asthenia, nausea and
vomiting or phlebitis, a dose reduction of 25% was left to
the discretion of the investigator. If the treatment had to be
delayed for more than 2 weeks, the patient was withdrawn
from the study. No prophylactic antiemetics were given for
the first cycle. If nausea and vomiting occurred conventional
antiemetics were given prophylactically for subsequent cycles.
Results
Thirty-one patients were entered into the study between April
1993 and February 1994. Twenty-seven patients were eligible
and had evaluable data. Two patients were ineligible and two
patients were not evaluable (Table I). The reasons for non-
eligibility were: lack of measurable lesions (one patient) and
too long a time interval (> 14 days) between the pretreatment
work-up, including tumour assessment, and start of the study
drug (one patient). Reasons for non-evaluability were an
early death on day 13 of the study due to an allergic reaction
to the contrast medium leading to a cardiac arrest while
undergoing a venogram (one patient) and a pleurodesis with
mitoxanthrone for pleural effusion after first study drug
































administration and no further follow-up studies performed
(one patient). A total of 118 courses were administered (1-16
cycles per patient).
The median cumulative dose given was 7.85 mg m-2 per
patient (range 2.0-32.3). The median dose intensity (mg m-2
per week) was 0.67 mg m-2 (range 0.50-0.68). A total of 109
courses (92%) were administered at 2 mg m-2. Dose
reduction to 1.5 mg m-2 was necessary for 7 (6%) of the
118 courses: for five cycles (4%) because of haematological
toxicity, for one cycle (< 1%) because of non-haematological
toxicity and in one cycle ( < I%) for both reasons.
Treatment delays occurred in 10 (8%) of the 118 cycles. In
five (4%) the delay was drug related. Disease progression (24
patients) was the most frequent reason for withdrawal from
the study. Other reasons for treatment discontinuation were
excessive asthenia in one patient, end of protocol in two
patients, deterioration of patients' status in one patient and
death in one patient.
Haematological toxicity: (Table II)
Haematological toxicity was generally mild. However,
because the protocol did not ask for weekly laboratory tests
to be performed, the scores for myelosuppression may be too
low. Leucopenia was encountered in 41% of the courses,
CTC grades 1 and 2 in 38 (32%) and CTC grades 3 and 4 in
nine (8%) of the cycles. For two courses (1%) the grade of
leucopenia was not available. Neutropenia CTC grades 3 and
4 was observed in 18 (15%) courses. Neutropenic fever
occurred in four patients. Anaemia and thrombocytopenia
were rare: anaemia CTC grade 3 was recorded in one course
(<1%) and thrombocytopenia CTC grade 1 in one course
(<1%).
Symptomatic toxicity: (Table III)
Alopecia was the most frequent side-effect. It was observed in
90% of the patients. Skin toxicity characterised by pruritic,
erythematous, vesiculopapillary lesions mainly involving the
head and neck and face and arms was recorded in 34% of the
courses, mainly of grades 1 and 2. Phlebitis and burning pain
along the vein during rhizoxin injection occurred in 20% of
the courses, mainly CTC grade 1. For four patients it was
rated as a CTC grade 2 toxicity, requiring a prolonged
infusion time (two patients) and pethidine administration was
required due to pain (one patient). Asthenia and fatigue was
observed in 30% of the courses mainly of CTC grades 1 and
2. Stomatitis was encountered in 30% of the courses,
generally mild, with only two courses showing CTC grade 3
toxicity. Nausea and vomiting were observed in 21% and 5%
Table H Drug-related haematological toxicity per cycle (n=118)
Common toxicity Total
criteria I II III IV Unknown (%)
Leucopenia 24 14 6 3 2 49 (42)
Neutropenia 16 14 8 10 - 48 (41)
Anaemia 36 6 1 - - 43 (38)
Thrombocytopenia 1 - - - - 1 (1)
Table m Drug-related symptomatic toxicity per cycle (n= 118)
Common toxicity
criteria I II III IV Total (%)
Alopecia 22 85 - - 107 (91)
Skin toxicity 16 23 1 - 40 (34)
Local (phlebitis) 21 4 - - 25 (21)
Stomatitis 10 28 2 - 40 (34)
Asthenia/malaise/fatigue 23 10 2 - 35 (30)
nausea 18 7 - - 25 (21)
Vomiting 2 3 - - 5 (4)Rhizoxin in non-small-cell lung cancer
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of the courses respectively. Diarrhoea, headache, allergic
hypersensitivity reactions and changes in taste were also
registered but their occurrence was rare and of mild nature.
Response to rhizoxin (Table IV)
The treatment response was evaluated initially after two
courses of chemotherapy and thereafter following every two
cycles. Four (14.8%) of 27 patients evaluable for response
[95% confidence interval (CI) 4.2-33.7%] showed a partial
response (all of bidimensional measurable lesions) to
rhizoxin. All objective responses were validated by indepen-
dent external review. Stable disease was found in 13 patients
(48%), while ten patients (37%) progressed during treatment.
Duration of response (partial response and no change) and
duration of survival were calculated from the start of
treatment. The responses lasted 6, 6.4, 8 and 10.7 months.
The median survival was 6 months (range 2-14.7).
Discussion
This phase II study has demonstrated that rhizoxin as a
single agent is active in NSCLC. It yielded a response rate of
15% validated by an independent external review, which
places rhizoxin among the drugs regarded as active in this
tumour type. Rhizoxin given i.v. at 2 mg m-2 every 3 weeks
to patients with advanced, non-resectable or metastatic
NSCLC, in good performance status, is generally well
tolerated. Haematological toxicity, confirming the results of
the phase I studies, was modest. Leucopenia and neutropenia
Table IV Response in 27 evaluable patients
Response No. ofpatients (%)
Partial remission 4 15
Stable disease 13 48
Progression 8 30
Early progression 2 7
CTC grades 3 and 4 were observed in 8% and 15% of the
courses respectively, and was rarely associated with infec-
tions. It was possible to give the majority of the 118 courses,
at a full dose, with only 7% requiring dose reduction due to
haematological toxicity. The most common symptomatic
toxicity was alopecia (90%). Stomatitis, asthenia and skin
manifestation were reported in 30-35% of the courses,
mainly of mild severity. Nausea was encountered in 21% of
the courses and vomiting in 5% of courses, but were
generally not troublesome.
Phlebitis and pain radiating along the vein from the
injection site was noted in 21% of the courses; two patients
required a prolonged administration time. For one patient
pethidine administration was necessary for pain control
during injection.
Rhizoxin is a new chemotherapeutic agent with a unique
mechanism of action, showing activity in NSCLC. Its modest
haematological and symptomatic toxicity makes rhizoxin an
attractive drug to investigate further in combination
chemotherapy and as an outpatient palliative treatment.
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